Your browser doesn't support javascript.
loading
Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib.
Rampotas, Alex; Carter-Brzezinski, Luke; Somervaille, Tim C P; Forryan, James; Panitsas, Fotios; Harrison, Claire; Witherall, Ruth; Innes, Andrew J; Wallis, Louise; Butt, Naumann M; Psaila, Bethan; Mead, Adam J; Carter, Matthew; Godfrey, Anna L; Laing, Heather; Garg, Mamta; Francis, Sebastian; Ewing, Joanne; Teh, Chun Huat; Cowen, Hannah Bibi; Dyer, Peter; McConville, Conall; Wadelin, Frances; Sahra, Ali; McGregor, Andrew; Kulakov, Elizabeth; McLornan, Donal P; Lambert, Jonathan.
Affiliation
  • Rampotas A; Haematology Department, University College London Hospital NHS Foundation Trust, London, United Kingdom.
  • Carter-Brzezinski L; Cancer Research UK Manchester Institute, Manchester, United Kingdom.
  • Somervaille TCP; Haematology Department, The Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Forryan J; Cancer Research UK Manchester Institute, Manchester, United Kingdom.
  • Panitsas F; Haematology Department, The Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Harrison C; Haematology Department, University College London Hospital NHS Foundation Trust, London, United Kingdom.
  • Witherall R; Haematology Department, Laikon University Hospital of Athens, Athens, Greece.
  • Innes AJ; Haematology Department, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
  • Wallis L; Haematology Department, Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom.
  • Butt NM; Haematology Department, Imperial College Healthcare NHS Trust, London, United Kingdom.
  • Psaila B; Haematology Department, University Hospitals Dorset NHS Foundation Trust, Bournemouth, United Kingdom.
  • Mead AJ; Haematology Department, The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, United Kingdom.
  • Carter M; Department of Haematology and NIHR Biomedical Research Centre, OUH NHS Foundation Trust, Oxford, United Kingdom.
  • Godfrey AL; Department of Haematology and NIHR Biomedical Research Centre, OUH NHS Foundation Trust, Oxford, United Kingdom.
  • Laing H; Haematology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
  • Garg M; Haematology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
  • Francis S; University Hospitals of Leicester NHS Trust, Leicester, United Kingdom.
  • Ewing J; University Hospitals of Leicester NHS Trust, Leicester, United Kingdom.
  • Teh CH; Haematology Department, Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom.
  • Cowen HB; Haematology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
  • Dyer P; Haematology Department, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.
  • McConville C; Haematology Department, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
  • Wadelin F; Haematology Department, University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom.
  • Sahra A; Department of Haematology, Altnagelvin Area Hospital, North West Cancer Centre, Derry, United Kingdom.
  • McGregor A; Haematology Department, Nottingham University Hospital NHS Foundation Trust, Nottingham, United Kingdom.
  • Kulakov E; Haematology Department, King's College London Hospital NHS Foundation Trust, London, United Kingdom.
  • McLornan DP; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom.
  • Lambert J; Dermatology Department, University College London Hospital NHS Foundation Trust, London, United Kingdom.
Blood ; 143(2): 178-182, 2024 Jan 11.
Article in En | MEDLINE | ID: mdl-37963262
ABSTRACT
ABSTRACT Nonmelanoma skin cancers (NMSCs) in ruxolitinib-treated patients with myeloproliferative neoplasms behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis. Vigilant skin assessment, counseling on NMSC risks, and prospective ruxolitinib-NMSC studies are crucial.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazoles / Pyrimidines / Skin Neoplasms / Myeloproliferative Disorders Limits: Humans Language: En Journal: Blood Year: 2024 Document type: Article Affiliation country: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazoles / Pyrimidines / Skin Neoplasms / Myeloproliferative Disorders Limits: Humans Language: En Journal: Blood Year: 2024 Document type: Article Affiliation country: United kingdom